Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 16, 2024 08:00 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS

Landmark publication in leading ophthalmology research journal demonstrates the power of 4DMT’s Therapeutic Vector Evolution platform to invent potentially best-in-class customized vectors and...
November 14, 2024 08:00 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV

EMERYVILLE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
November 13, 2024 16:05 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse...
September 23, 2024 08:00 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference

EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
September 18, 2024 16:05 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day

4D-150 demonstrated robust and durable clinical activity across all wet age-related macular degeneration (wet AMD) patient populations based on longest available follow-up data In broad population...
September 05, 2024 08:00 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Announces Presentations at Upcoming Retina Conferences

EMERYVILLE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
September 03, 2024 08:00 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT to Participate in the 2024 Cantor Global Healthcare Conference

EMERYVILLE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
August 27, 2024 08:00 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024

Company to highlight 4D-150 product development strategy and Phase 1/2 PRISM clinical trial data in wet age-related macular degeneration (wet AMD), including longest available interim follow-up data ...
August 12, 2024 08:00 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

EMERYVILLE, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
August 08, 2024 16:05 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights

Announced positive interim results from the Population Extension cohort of the Phase 2 PRISM clinical trial for 4D-150 in a broad wet age-related macular degeneration (wet AMD) population, which...